TuisGRAL • NASDAQ
add
Grail Inc
Vorige sluiting
$39,49
Dagwisseling
$36,94 - $40,88
Jaarwisseling
$12,33 - $63,99
Markkapitalisasie
1,38 mjd USD
Gemiddelde volume
1,50 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 31,84 m | 19,15% |
Bedryfskoste | 133,71 m | -34,94% |
Netto inkomste | -106,21 m | 51,48% |
Netto winsgrens | -333,61 | 59,28% |
Wins per aandeel | -3,10 | — |
EBITDA | -114,36 m | 38,98% |
Effektiewe belastingkoers | 27,46% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 674,58 m | 237,76% |
Totale bates | 2,85 mjd | -28,32% |
Totale aanspreeklikheid | 433,94 m | 85,87% |
Totale ekwiteit | 2,41 mjd | — |
Uitstaande aandele | 35,97 m | — |
Prys om te bespreek | 0,58 | — |
Opbrengs op bates | -13,17% | — |
Opbrengs op kapitaal | -15,21% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -106,21 m | 51,48% |
Kontant van bedrywe | -95,01 m | 54,16% |
Kontant van beleggings | 14,61 m | 673,43% |
Kontant van finansiering | — | — |
Netto kontantverandering | -80,34 m | -178,66% |
Beskikbare kontantvloei | -38,94 m | 61,34% |
Meer oor
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California. It was previously a subsidiary of Illumina started as a startup seeking to develop an early cancer screening test for people who do not have symptoms.
Grail was spun-out from Illumina on June 24, 2024.
Their liquid biopsy was launched in June 2021 and is called the Galleri test. Promoted as groundbreaking, the test performed poorly in testing and Grail has subsequently faced discontent and legal action from investors claiming they have been misled about the test's potential. Wikipedia
Gestig
2015
Webwerf
Werknemers
1 000
